FDA approves Novartis high blood pressure drug Tekturna

The FDA gave Novartis AG clearance to market its Tekturna drug to treat high blood pressure, breathing new life into a product the firm had almost given up on seven years ago. Developed with Speedel Holding AG, the drug at one time was considered too expensive to make but now emerges as the first new type of drug in more than a decade for treating high blood pressure.

View Full Article in:

Bloomberg Businessweek · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX